FDA ODAC refuses to back AVEO RCC drug tivozanib
This article was originally published in Scrip
All but one of the 14 advisers to the US FDA on 2 May said AVEO had failed to demonstrate a favorable benefit-to-risk evaluation for its experimental tyrosine kinase inhibitor tivozanib as a treatment for patients with renal cell carcinoma (RCC) in a adequate and well-controlled trial.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.